AC Immune S.A.
NASDAQ:ACIUBiotechnology
Healthcare
$2.11 +1.71%
+$0.04 today
- Market cap
- $214.74M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
52W Low $1.65High $4.00
Volume 0.12M
Average 0.32M
Income Statement
Follow revenue through to earnings.
Revenue
$3.57M
FY 2025 · Annual
-86.9% YoYOperating Income
-$68.86M
FY 2025 · Annual
Net Income
-$70.45M
FY 2025 · Annual
Income Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| 74.95M | 83.55M | 84.69M | 99.69M | 100.75M | |
| 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
ACIU Earnings Waterfall · TTM
NASDAQ:ACIU · Revenue to Net Income
Key Ratios
EPS$-0.66
Gross Margin100.0%
Net Margin-2221.6%
P/E Ratio-3.4
P/S Ratio326.4
Analysis
$3.7M of revenue converted into -$66.2M of net income for the selected period. Gross margin is 100.0% and net margin is -2221.6%, showing how much revenue survives after costs and taxes. EPS is $-0.66, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 4, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 9, 2026 | |
| 3/A | 3/A filing | Oct 9, 2026 | |
| 6-K | 6-K filing | Oct 2, 2026 | |
| 6-K | 6-K filing | Sep 23, 2026 |
How much revenue does ACIU generate?
AC Immune S.A. (ACIU) reported $3.57M of revenue in fiscal 2025.
Is ACIU profitable?
AC Immune S.A. (ACIU) reported -$70.45M of net income, with a net margin of -1971.6%.
Continue the stock analysis
Jump to another research area for this company.